NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
Rhea-AI Summary
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET the same day and provide a live webcast and replay.
Dial-in numbers, replay access code 11161124, and a 90-day archived webcast will be available for investors and analysts.
Positive
- None.
Negative
- None.
News Market Reaction – NXGL
In the Mar 25 session, NXGL declined 0.97%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.1% during that session. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Acquisition terms update | Positive | +16.2% | Detailed financial and strategic terms for Celularity biomaterials acquisition. |
| Mar 10 | Definitive acquisition deal | Positive | -15.8% | Signed definitive agreement for revenue-accretive regenerative biomaterials portfolio. |
| Feb 10 | Acquisition financing | Positive | +2.3% | Announced $1.797M financing tied to a targeted Q1 2026 acquisition. |
| Dec 16 | Spin-off investment | Positive | +3.1% | New investment and strategic advisor for NexGelRx spin-off entity. |
| Dec 11 | Drug delivery spin-off | Positive | +22.7% | Announced spin-off of drug delivery program into NexGelRx with royalties and equity. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been followed by positive reactions, with 4 aligned moves and 1 divergence, suggesting the stock often responds constructively to strategic developments.
Over the last several months, NEXGEL has focused on strategic expansion and portfolio restructuring. In Dec 2025 it announced and then funded the NexGelRx spin-off, retaining royalties, equity, and exclusive manufacturing. In early 2026, the company arranged acquisition-related financing and then signed and detailed a transformative regenerative biomaterials deal expected to significantly lift revenue and profitability. These moves frame the upcoming Q4 and full-year 2025 earnings date as an update point against an active strategic backdrop.
Key Terms
otc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management will host a conference call at 4:30 P.M. ET on the same day
LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.
Fourth Quarter and Full Year 2025 Financial Results Conference Call
Date: March 31, 2026
Time: 4:30 P.M. ET
Live Call: 1-833-316-1983 (U.S. Toll Free) or 1-785-838-9310 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through April 14, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11161124. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
